Focal Point Pharmaceuticals, Inc. is an early stage company developing products for ocular diseases.  The company’s technology was initially developed by leading institutions for childhood disorders.  The company has recently been awarded a major federal grant in conjunction with a leading university and is moving forward with preclinical research and lead selection.  The aim of the company is to provide new therapeutics for at least two rare diseases that would be granted orphan status by the US FDA.